Publicaciones científicas

De Novo Malignancy After Liver Transplantation: Risk Assessment, Prevention, and Management-Guidelines From the ILTS-SETH Consensus Conference

01-ene-2022 | Revista: Transplantation

Jordi Colmenero  1 , Parissa Tabrizian  2 , Prashant Bhangui  3 , David James Pinato  4 , Manuel L Rodríguez-Perálvarez  5 , Gonzalo Sapisochin  6 , Sherrie Bhoori  7 , Sonia Pascual  8 , Marco Senzolo  9 , David Al-Adra  10 , J Ignacio Herrero  11 , Henrik Petrowsky  12 , Laura A Dawson  13 , Ali Hosni  13 , Jade L Kutzke  14 , Mikel Gastaca  15 , Kymberly D Watt  16


De novo malignancies (DNMs) following liver transplantation (LT) have been reported as 1 of the major causes of late mortality, being the most common cause of death in the second decade after LT.

The overall incidence of DNMs is reported to be in the range of 3.1% to 14.4%, and the incidence is 2- to 3-fold higher in transplant recipients than in age- and sex-matched healthy controls.

Long-term immunosuppressive therapy, which is the key in maintaining host tolerance and achieving good long-term outcomes, is known to contribute to a higher risk of DNMs.

However, the incidence and type of DNM also depends on different risk factors, including patient demographics, cause of the underlying chronic liver disease, behavior (smoking and alcohol abuse), and pre-existing premalignant conditions. The estimated standardized incidence ratio for different DNMs is also variable.

The International Liver Transplantation Society-Spanish Society of Liver Transplantation Consensus Conference working group on DNM has summarized and discussed the current available literature on epidemiology, risk factors, management, and survival after DNMs.

Recommendations for screening and surveillance for specific tumors, as well as immunosuppression and cancer-specific management in patients with DNM, are summarized.

CITA DEL ARTÍCULO  Transplantation. 2022 Jan 1;106(1):e30-e45.
doi: 10.1097/TP.0000000000003998